Alaunos Therapeutics, Inc. — Form 8-K
Filed September 22, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 12/100
What the filing says
Alaunos Therapeutics sold 380,469 shares at $1.46/share and pre-funded warrants to purchase 386,654 shares at $0.001 exercise price, totaling $1,120,000.54 gross proceeds. Placement agent Dawson James receives 8% fee ($89,600). Securities are registered under Form S-3 effective November 27, 2025, with lock-up agreements from officers and directors.
Why this rating
Routine registered offering at ~11.7% of company market cap. Dilution and small cash infusion typical for micro-cap biotech. No material operational change evident.
See more from September 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.